Sign In
Buy PCRX
$26.41
-0.560 (-2.08%)
At Close: Jul 31, 2026
Pacira Biosciences (NASDAQ:PCRX) Trading Up 0.6% Following Analyst Upgrade
01:26pm, Tuesday, 30'th Jun 2020
Pacira Biosciences Inc (NASDAQ:PCRX) shares were up 0.6% during trading on Tuesday after SVB Leerink raised their price target on the stock from $45.00 to $58.00. SVB Leerink currently has an outperfo
Northland Securities Maintains a Buy Rating on Verrica Pharmaceuticals (VRCA) - Markets
11:49am, Tuesday, 30'th Jun 2020
Northland Securities analyst Tim Chiang maintained a Buy rating on Verrica Pharmaceuticals (VRCA – Research Report) today and set a
Key Companies Profiled are MIRA Rehab Limited, Jintronix., Doctor On Demand, Inc., Care Innovations, LLC., American Well, NeoRehab, Hinge Health, Inc., Koninklijke Philips N.V. and other key market pl
Why Pacira BioSciences Is Soaring Today | The Motley Fool
04:58pm, Monday, 29'th Jun 2020
Thanks to a recent FDA decision, its best-selling product, Exparel, will go at least a little longer without facing competition from Heron Therapeutics' HTX-011.
Heron Therapeutics (HRTX) Initiated with a Buy at Stifel Nicolaus - Markets
03:44pm, Monday, 29'th Jun 2020
Stifel Nicolaus analyst Derek Archila initiated coverage with a Buy rating on Heron Therapeutics (HRTX – Research Report) today and
U.S. FDA again declines to approve Heron Therapeutics' non-opioid painkiller
02:04pm, Monday, 29'th Jun 2020
Heron Therapeutics said on Monday the U.S. Food and Drug Administration has once again declined to approve its non-opioid painkiller for post-operative pain and sought more data, sending its shares do
U.S. FDA seeks more data on Heron Therapeutics' non-opioid painkiller
01:00pm, Monday, 29'th Jun 2020Pacira Biosciences (NASDAQ:PCRX) Sets New 1-Year High at $52.32
11:10am, Monday, 29'th Jun 2020
Pacira Biosciences Inc (NASDAQ:PCRX)’s stock price hit a new 52-week high on Monday . The company traded as high as $52.32 and last traded at $51.90, with a volume of 565611 shares traded. The stock
Stifel Nicolaus Believes Momenta Pharma (NASDAQ: MNTA) Won't Stop Here - Markets
09:09pm, Wednesday, 24'th Jun 2020
Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Momenta Pharma (MNTA – Research Report) today. The company’s shares
Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (NASDAQ: KPTI) and Pfizer (NYSE: PFE) - Markets
10:27am, Tuesday, 23'rd Jun 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics
Two Sigma Investments LP Cuts Stock Position in Pacira Biosciences Inc (NASDAQ:PCRX)
08:34am, Monday, 22'nd Jun 2020
Two Sigma Investments LP lessened its position in Pacira Biosciences Inc (NASDAQ:PCRX) by 69.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission.
Pacira Biosciences Inc (NASDAQ:PCRX) Shares Sold by Nuveen Asset Management LLC
05:56am, Saturday, 20'th Jun 2020
Nuveen Asset Management LLC reduced its holdings in Pacira Biosciences Inc (NASDAQ:PCRX) by 18.5% during the first quarter, according to the company in its most recent filing with the SEC. The fund ow
Stifel Nicolaus Remains a Hold on Selecta Biosciences (SELB) - Markets
01:47pm, Thursday, 18'th Jun 2020
Stifel Nicolaus analyst Derek Archila reiterated a Hold rating on Selecta Biosciences (SELB – Research Report) today. The company’s shares
Stifel Nicolaus Keeps Their Hold Rating on Amarin (AMRN) - Markets
10:35pm, Tuesday, 16'th Jun 2020
Stifel Nicolaus analyst Derek Archila reiterated a Hold rating on Amarin (AMRN – Research Report) today. The company’s shares closed
Pacira BioSciences to Present at the 2020 BMO Prescriptions for Success Healthcare Conference
11:30am, Tuesday, 16'th Jun 2020
PARSIPPANY, N.J., June 16, 2020 -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 BMO Prescriptions for Success Healthcare Conference.
